Recent Updates
Recently added Catalysts

MK0782

Phase 2

Stomach Ulcer | Small molecule | Other |Merck & Company, Inc.|Last Updated: Jun 11, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment462
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00543868MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)PHASE2 COMPLETED 462Jun 1, 2004Aug 1, 2004Jun 11, 2015 -
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Interventions
NameTypeDescription
MK0782DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Healthy male or non pregnant female * 18 years of age or older (age at consent) * Able to abstain from alcohol, tobacco, spicy foods, limit coffee * Able to avoid strenuous activity * Able to read and fill out a study diary Exclusion Criteria: * You have participated in an i...

Unlock Eligibility Criteria